Cenobamate Drug Development and Commercial rights for Europe Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Cenobamate Drug Development and Commercial rights for Europe General Information
Description
Development and Commercial rights of a drug for Europe based in Switzerland.
Contact Information
Corporate Office
- Zählerweg 6
- 6300 Zug
- Switzerland
Corporate Office
- Zählerweg 6
- 6300 Zug
- Switzerland
Cenobamate Drug Development and Commercial rights for Europe Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Cenobamate Drug Development and Commercial rights for Europe Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Cenobamate Drug Development and Commercial rights for Europe FAQs
-
Where is Cenobamate Drug Development and Commercial rights for Europe headquartered?
Cenobamate Drug Development and Commercial rights for Europe is headquartered in Zug, Switzerland.
-
What industry is Cenobamate Drug Development and Commercial rights for Europe in?
Cenobamate Drug Development and Commercial rights for Europe’s primary industry is Buildings and Property.
-
Is Cenobamate Drug Development and Commercial rights for Europe a private or public company?
Cenobamate Drug Development and Commercial rights for Europe is a Private company.
-
What is the current valuation of Cenobamate Drug Development and Commercial rights for Europe?
The current valuation of Cenobamate Drug Development and Commercial rights for Europe is .
-
What is Cenobamate Drug Development and Commercial rights for Europe’s current revenue?
The current revenue for Cenobamate Drug Development and Commercial rights for Europe is .
-
Who are Cenobamate Drug Development and Commercial rights for Europe’s investors?
SK Biopharmaceuticals has invested in Cenobamate Drug Development and Commercial rights for Europe.
-
When was Cenobamate Drug Development and Commercial rights for Europe acquired?
Cenobamate Drug Development and Commercial rights for Europe was acquired on 20-Feb-2019.
-
Who acquired Cenobamate Drug Development and Commercial rights for Europe?
Cenobamate Drug Development and Commercial rights for Europe was acquired by Arvelle Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process